Time filter

Source Type

News Article | December 12, 2016
Site: www.eurekalert.org

"Through the Installation Grants we encourage some of the best early-career researchers to share their expertise across Europe by setting up laboratories in selected EMBC Member States," explains EMBO Director Maria Leptin. "Each year, we receive applications from outstanding scientists, and it is a pleasure to be able to support them during this challenging career phase in order to establish scientific excellence across the whole continent." EMBO Installation Grants are awarded annually. They are funded primarily by the participating Member States Estonia, Poland, Portugal, Turkey and the Czech Republic. Grantees are selected by a committee of EMBO Members on the basis scientific excellence as the primary selection criterion. Each Installation Grantee receives 50,000 euros annually for three to five years to support the establishment of an independent research group. In addition to financial support, the recipients receive networking opportunities and practical support by becoming part of the EMBO Young Investigator network. Since 2006, EMBO has supported 89 group leaders through Installation Grants. Of the most recent awardees, four will establish laboratories in Turkey, two in Poland, two in Portugal, one in Estonia, and one in the Czech Republic. The next application deadline for EMBO Installation Grants is 15 April 2017. Melih Acar, Hematopoietic stem cell regulation, moving to Bahcesehir University, School of Medicine, Istanbul, TR, from UT Southwestern Medical Center, Dallas, TX, US Jaan-Olle Andressoo, Gene knock-up to treat Parkinson's disease, moving to Tallinn Institute of Technology, EE, from University of Helsinki, FI Claus Maria Azzalin, Telomeres, cancer and aging, moving to Institute of Molecular Medicine, Lisbon, PT, from Institute of Biochemistry, ETH Zurich, CH Murat Alper Cevher, Characterization of mediator-estrogen receptor interaction, moving to Bilkent University, Ankara, TR, from Rockefeller University, NY, US Rafal Ciosk, Cell fate plasticity in development and tissue homeostasis, moving to Institute of Bioorganic Chemistry, Poznan, PL, from Friedrich Miescher Institute for Biomedical Research, Basel, CH Elif Nur Firat-Karalar, Function and regulation of the centrosome/cilium complex, moving to Koç University, Istanbul, TR, from Stanford University, CA, USA Catarina Homem, Temporal and metabolic regulation of stem cells, Chronic Diseases Research Center, moving to Nova Medical School, PT, from Institute of Molecular Biotechnology of Austria, Vienna, AT Abdullah Kahraman, Non-coding cancer driver mutations in isoform networks, moving to Sabanci University, Istanbul, TR, from Institute of Molecular Life Sciences, University of Zurich, CH Vladimír Varga, Construction of the eukaryotic flagellum, moving to Institute of Molecular Genetics of the ASCR, Prague, CZ, from University of Oxford, UK Piotr Ziolkowski, Crossover control in plants, moving to Adam Mickiewicz University, Poznan, PL, from University of Cambridge, Cambridge, UK EMBO is an organization of more than 1700 leading researchers that promotes excellence in the life sciences. The major goals of the organization are to support talented researchers at all stages of their careers, stimulate the exchange of scientific information, and help build a European research environment where scientists can achieve their best work. EMBO helps young scientists to advance their research, promote their international reputations and ensure their mobility. Courses, workshops, conferences and scientific journals disseminate the latest research and offer training in techniques to maintain high standards of excellence in research practice. EMBO helps to shape science and research policy by seeking input and feedback from our community and by following closely the trends in science in Europe. ?For more information: http://www. The European Molecular Biology Conference (EMBC) is an intergovernmental organization comprising 29 Member States. EMBC promotes a strong transnational approach to the life sciences. Within EMBC, Member States pool their resources to improve the quality of research at a national level and to contribute to the advancement of basic research in Europe. For more information: http://www.


News Article | October 23, 2015
Site: www.nature.com

In this Letter, author Yong-Bin Yan was incorrectly associated with affiliation number 5 (Department of Ophthalmology, Xijing Hospital) instead of affiliation number 4 (State Key Laboratory of Membrane Biology, School of Life Sciences, Tsinghua University, Beijing 100084, China). Also, an additional affiliation has been added to author Kang Zhang (number 15; Institute of Molecular Medicine, Peking University, Beijing 100871, China), and affiliation number 3 has changed from ‘Department of Ophthalmology and Biomaterials and Tissue Engineering Center’ to ‘Shiley Eye Institute and Biomaterials and Tissue Engineering Center’. These have all been corrected in the online versions of the paper.


News Article | December 1, 2015
Site: www.rdmag.com

Sinica, a subsidiary of Boyalife Group, has signed a deal to establish a $31 million commercial animal cloning facility in Tianjin, China, with the intent to produce beef cattle, racehorses and other animals. According to Xu Xiaochun, the board chairman of Boyalife Group, the plant will initially produce 100,000 cattle embryos per year, eventually increasing its output to 1,000,000 per year. Chinese farmers are struggling to produce enough beef cattle to meet market demand, said Xiaochun. According to Popular Science, China’s meet demand has quadrupled in the last 40 years. The new facility will be built by Sinica, Peking Univ.’s Institute of Molecular Medicine, the Tianjin International Joint Academy of Biomedicine and the Republic of Korea’s Sooam Biotech Research Foundation. Chinese scientists, according to Boyalife Group, have been cloning sheep, cattle and pigs since 2000. In September 2014, Boyalife and Sooam Biotech opened the first commercial cloning company in China’s Shandong Province. The first animals produced were three pure-blooded Tibetan mastiff puppies. Cloning animals for human consumption has been a contentious issue. Recently, the European Union (EU) made strides to ban imports of cloned animals and products made from cloned animals. Giulia Moi, the EU’s agriculture committee co-rapporteur noted European farmers are facing increasing pressure from Asia due to practices such as cloning. However, the U.S. Food and Drug Administration in 2008 determined meat and milk from clones and their offspring pose no substantial threat when compared with food eaten every day. According to Agence France-Presse, Boyalife Group hopes to hit the 1,000,000 production goal by 2020. Additionally, the company is working with partners to improve primate cloning for disease research purposes. From there, it’s on to humans, if allowed. “The technology is already there,” said Xiaochun to Agence France-Presse. “If this is allowed, I don’t think there are other companies better than Boyalife that make better technology.” In the future, the technology may be applied to reproduction, allowing parents more choice their child’s genetic makeup, Xiaochun suggested.


Grant
Agency: Cordis | Branch: FP7 | Program: CP-SICA | Phase: HEALTH-2007-2.3.2-12 | Award Amount: 3.94M | Year: 2008

The increasing emergence of multidrug resistant strains and extensively drug resistant strains, the last one being virtually untreatable, urgently demand novel drugs for therapy of tuberculosis. This project has the aim of bringing together a number of research scientists with expertise in a broad range of disciplines, both from Europe and from India, covering the development field from chemistry to in vivo evaluation. The selected targets belong to either the group of targets from which some proof of concept already exist (mycolic acid synthesis and ATP synthase) either to the group of completely new targets that will be validated (thymidylate synthase, acyl-CoA carboxylase, DNA helicases). One alternative strategy to target the host cellular machinery to enhance bacterial killing is, likewise, included. The selected targets are covering fatty acid metabolism, nucleoside synthesis, energy generator, the survival of the microorganism in macrophages, the nucleic acids metabolism. The systems selected include those from which we expect to generate compounds active against replicating mycobacteria or to obtain compounds targeting latent infection. The application is divided in four scientific workpackages, including target validation, the interaction with the host cellular machinery, the design and synthesis of new inhibition and in vitro and in vivo screening of drug candidates and one management workpackage. A considerable part of the drug development and assessment against drug resistant Mycobacterium tuberculosis will be carried out by the Indian partners, one of which is an SME.


WINDBER, Pa.--(BUSINESS WIRE)--Chan Soon-Shiong Institute of Molecular Medicine at Windber, a private, non-profit biomedical research institute, today announced that the Chan Soon-Shiong Biobank at Windber (CSSBW) has been certified by the U.S. Department of Health and Human Services' Centers for Medicare & Medicaid Services under the Clinical Laboratory Improvement Acts of 1988 (CLIA). This certification follows the accreditation by the College of American Pathologists (CAP) in 2015, round


Home > Press > JPK’s NanoWizard® AFM is used to evaluate the risk of cardiovascular disease in patients at iMM, University of Lisbon Abstract: JPK Instruments, a world-leading manufacturer of nanoanalytic instrumentation for research in life sciences and soft matter, reports on the use of their NanoWizard® AFM system at the Instituto de Medicina Molecular at the University of Lisbon. Dr Nuno C Santos leads the Biomembranes and Nanomedicine group at the Institute of Molecular Medicine (iMM) at the University of Lisbon, Portugal. Driven by the fact that cardiovascular diseases are the leading cause of mortality worldwide, accounting for about one third of all deaths and that biomarkers for assessing cardiovascular risk still have a limited applicability, there is much potential for research into new solutions. High levels of fibrinogen, a protein essential for the blood clotting process, have been identified as a potential risk factor for these diseases and it is this topic that the group has applied atomic force microscopy (AFM) to study. Applying a NanoWizard® AFM system from JPK Instruments, the group has evaluated the interaction between fibrinogen and erythrocytes from patients with chronic heart failure, understanding how fibrinogen influences the aggregation of these cells. Dr Santos takes up the story to date: “We showed that the force required to break the bond between fibrinogen and erythrocyte is higher in patients with chronic heart failure than in healthy donors. Erythrocytes from these patients also showed changes in their elasticity and behavior while in the blood stream. Subsequently, during a one-year clinical follow-up, it was found that patients, where a higher force was initially required to release the binding between fibrinogen and erythrocytes, were more likely to be hospitalized due to cardiovascular complications in the following 12 months. We have been able to demonstrate a connection between nanotechnology and the identification of cardiovascular problems.” In this study, AFM-based methodology proved to be a promising nanotool to evaluate changes in the interaction between fibrinogen and human blood cells, pinpointing patients with increased cardiovascular risk. Fibrinogen-erythrocyte binding forces, measured at the single molecule level, are thus a potential biomarker for chronic heart failure severity and may eventually be used also for the clinical prognostic assessment of other cardiovascular diseases. Describing why he chose the NanoWizard®, Dr Santos continued: “Atomic force microscopy-based force spectroscopy using the NanoWizard® II from JPK instruments was our first choice to study the interaction between fibrinogen and red blood cells and evaluated the cell elasticity in chronic heart failure disease. This has provided us with a robust and user-friendly system for this research.” Lastly, the group has recently had a publication in Nature Nanotechnology. Entitled Atomic force microscopy as a tool to evaluate the risk of cardiovascular diseases in patients, the paper follows the work described here and reaches the conclusion that AFM is a promising tool to identify patients with increased risk for cardiovascular diseases.1 For more details about JPK's NanoWizard® AFM and its applications for the bio & nano sciences, please contact JPK on +49 30726243 500. Alternatively, please visit the web site: www.jpk.com/ or see more on Facebook: www.jpk.com/facebook and on You Tube: www.youtube.com/jpkinstruments. Reference 1 Ana Filipa Guedes et al, Atomic force microscopy as a tool to evaluate the risk of cardiovascular diseases in patients; Nature Nanotechnology11, 687-692 (2016)doi:10.1038/nnano.2016.52 About JPK Instruments JPK Instruments AG is a world-leading manufacturer of nanoanalytic instruments - particularly atomic force microscope (AFM) systems and optical tweezers - for a broad range of applications reaching from soft matter physics to nano-optics, from surface chemistry to cell and molecular biology. From its earliest days applying atomic force microscope (AFM) technology, JPK has recognized the opportunities provided by nanotechnology for transforming life sciences and soft matter research. This focus has driven JPK's success in uniting the worlds of nanotechnology tools and life science applications by offering cutting-edge technology and unique applications expertise. Headquartered in Berlin and with direct operations in Dresden, Cambridge (UK), Singapore, Tokyo, Shanghai (China), Paris (France) and Carpinteria (USA), JPK maintains a global network of distributors and support centers and provides on the spot applications and service support to an ever-growing community of researchers. For more information, please click If you have a comment, please us. Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.


News Article | December 27, 2016
Site: www.eurekalert.org

The Biophysical Society has announced the winners of its international travel grants to attend the Biophysical Society's 61st Annual Meeting in New Orleans, February 11-15, 2017. The purpose of these awards is to foster and initiate further interaction between American biophysicists and scientists working in countries experiencing financial difficulties. Recipients of this competitive award are chosen based on scientific merit and their proposed presentation at the meeting. They will be honored at a reception on Sunday, February 12 at the Ernest N. Morial Convention Center. The 2017 recipients of the International Travel Award, along with their institutional affiliation and abstract title, are listed below. Ana F. Guedes, Institute of Molecular Medicine, Portugal, ATOMIC FORCE MICROSCOPY AS A TOOL TO EVALUATE THE RISK OF CARDIOVASCULAR DISEASES IN PATIENTS. Karishma Bhasne Mohali, Indian Institute of Science Education and Research (IISER), A TALE OF TWO AMYLOIDOGENIC INTRINSICALLY DISORDERED PROTEINS: INTERPLAY OF TAU AND α-SYNUCLEIN. Chan Cao, East China University of Science and Technology, DIRECT IDENTIFICATION OF ADENINE, THYMINE, CYTOSINE AND GUANINE USING AEROLYSIN NANOPORE. Venkata Reddy Chirasani, Indian Institute of Technology Madras, LIPID TRANSFER MECHANISM OF CETP BETWEEN HDL AND LDL: A COARSEGRAINED SIMULATION STUDY. Assaf Elazar, Weizmann Institute of Science, Israel, DECIPHERING MEMBRANE PROTEIN ENERGETICS USING DEEP SEQUENCING; TOWARDS ROBUST DESIGN AND STRUCTURE PREDICTION OF MEMBRANE PROTEINS. Manuela Gabriel, University of Buenos Aires, Argentina, 3D ORBITAL TRACKING OF SINGLE GOLD NANOPARTICLES: A NEW APPROACH TO STUDY VESICLE TRAFFICKING IN CHROMAFFIN CELLS. Farah Haque National Centre for Biological Sciences, India, A NEW HUMANIZED MOUSE MODEL FOR STUDYING INHERITED CARDIOMYOPATHIC MUTATIONS IN THE MYH7 GENE. Stephanie Heusser, Stockholm University, Switzerland, STRUCTURAL AND FUNCTIONAL EVIDENCE FOR MULTI-SITE ALLOSTERY MEDIATED BY GENERAL ANESTHETICS IN A MODEL LIGAND-GATED ION CHANNEL. Amir Irani, Massey University, New Zealand, HOMOGALACTURONANS ILLUMINATE THE ROLE OF COUNTERION CONDENSATION IN POLYELECTROLYTE TRANSPORT. Olfat Malak, University of Nantes, France, HIV-TAT INDUCES A DECREASE IN IKR AND IKS VIA REDUCTION IN PHOSPHATIDYLINOSITOL-(4,5)-BISPHOSPHATE AVAILABILITY. CONFORMATIONAL TRANSITION AND ASSEMBLY OF E.COLI CYTOLYSIN A PORE FORMING TOXIN BY SINGLE MOLECULE FLUORESCENCE. Sabrina Sharmin, Shizuoka University, Japan, EFFECTS OF LIPID COMPOSITIONS ON THE ENTRY OF CELL PENETRATING PEPTIDE OLIGOARGININE INTO SINGLE VESICLES. Xin Shi, East China University of Science and Technology, DIRECT OBSERVATION OF SINGLE BIOPOLYMER FOLDING AND UNFOLDING PROCESS BY SOLIDSTATE NANOPORE. Omar Alijevic, University of Lausanne, Switzerland, ANALYSIS OF GATING OF ACID-SENSING ION CHANNELS (ASICS) UNDER RAPID AND SLOW PH CHANGES. Swapna Bera, Bose Institute, India, BIOPHYSICAL INSIGHTS INTO THE MEMBRANE INTERACTION OF THE CORE AMYLOID-FORMING Aβ40 FRAGMENT K16-K28 AND ITS ROLE IN THE PATHOGENESIS OF ALZHEIMER'S DISEASE. Anais Cassaignau, University College London, United Kingdom, STRUCTURAL INVESTIGATION OF AN IMMUNOGLOBULIN DOMAIN ON THE RIBOSOME USING NMR SPECTROSCOPY. Bappaditya Chandra, Tata Institute of Fundamental Research, India, SECONDARY STRUCTURE FLIPPING CONNECTED TO SALT-BRIDGE FORMATION CONVERTS TOXIC AMYLOID-β40 OLIGOMERS TO FIBRILS. Gayathri Narasimhan, Cinvestav, Mexico, ANTIHYPERTROPHIC EFFECTS OF DIAZOXIDE INVOLVES CHANGES IN MIR-132 EXPRESSION IN ADULT RAT CARDIOMYCYTES. Giulia Paci, European Molecular Biology Laboratory, Germany, FOLLOWING A GIANT'S FOOTSTEPS: SINGLE-PARTICLE AND SUPER-RESOLUTION APPROACHES TO DECIPHER THE NUCLEAR TRANSPORT OF HEPATITIS B VIRUS CAPSIDS. Bizhan Sharopov, Bogomoletz Institute of Physiology National Academy of Sciences of Ukraine, DISSECTING LOCAL AND SYSTEMIC EFFECTS OF TRPV1 ON BLADDER CONTRACTILITY IN DIABETES. Chao Sun, East China Normal University, FUNCTION OF BACTERIORUBERIN IN ARCHAERHODOPSIN 4, FROM EXPRESSION TO CHARACTERIZATION. Matthew Batchelor, University of Leeds, United Kingdom STRUCTURAL DYNAMICS IN THE MYOSIN 7A SINGLE α-HELIX DOMAIN. Daniel Havelka, Czech Academy of Sciences, MICROVOLUME DIELECTRIC SPECTROSCOPY AND MOLECULAR DYNAMICS OF AMINO ACIDS. Ivan Kadurin, University College London, United Kingdom, INVESTIGATION OF THE PROTEOLYTIC CLEAVAGE OF α2δ SUBUNITS: A MECHANISTIC SWITCH FROM NHIBITION TO ACTIVATION OF VOLTAGE-GATED CALCIUM CHANNELS? Linlin Ma, University of Queensland, Australia, NOVEL HUMAN EAG CHANNEL ANTAGONISTS FROM SPIDER VENOMS. Ivana Malvacio, University of Cagliari, Italy, MOLECULAR INSIGHTS ON THE RECOGNITION OF SUBSTRATES BY THE PROMISCUOUS EFFLUX PUMP ACRB. Cristina Moreno Vadillo, Cardiovascular Research Institute Maastricht, Netherlands, RESTORING DEFECTIVE CAMP-DEPENDENT UPREGULATION IN LONG-QT SYNDROME TYPE-1 THROUGH INTERVENTIONS THAT PROMOTE IKS CHANNEL OPENING. Melanie Paillard, Claude Bernard University Lyon 1, France, TISSUE-SPECIFIC MITOCHONDRIAL DECODING OF CYTOPLASMIC CA2+ SIGNALS IS CONTROLLED BY THE STOICHIOMETRY OF MICU1/2 AND MCU. Mohammed Mostafizur Rahman, Institute for Stem Cell Biology and Regenerative Medicine, India, STRESS-INDUCED DIFFERENTIAL REGULATION LEADS TO DECOUPLING OF THE ACTIVITY BETWEEN MPFC AND AMYGDALA. Marcin Wolny, University of Leeds, United Kingdom, DESIGN AND CHARACTERIZATION OF LONG AND STABLE DE NOVO SINGLE α-HELIX DOMAINS. Elvis Pandzic, University of New South Wales, Australia, VELOCITY LANDSCAPES RESOLVE MULTIPLE DYNAMICAL POPULATIONS FROM FLUORESCENCE IMAGE TIME SERIES. The Biophysical Society, founded in 1958, is a professional, scientific Society established to encourage development and dissemination of knowledge in biophysics. The Society promotes growth in this expanding field through its annual meeting, monthly journal, and committee and outreach activities. Its 9000 members are located throughout the U.S. and the world, where they teach and conduct research in colleges, universities, laboratories, government agencies, and industry. For more information on these awards, the Society, or the 2017 Annual Meeting, visit http://www.


Chang J.-Y.,University of Houston | Chang J.-Y.,Institute of Molecular Medicine
Biochemistry | Year: 2011

The pathway of oxidative folding of disulfide proteins exhibits a high degree of diversity, which is manifested mainly by distinct structural heterogeneity and diverse rearrangement pathways of folding intermediates. During the past two decades, the scope of this diversity has widened through studies of more than 30 disulfide-rich proteins by various laboratories. A more comprehensive landscape of the mechanism of protein oxidative folding has emerged. This review will cover three themes. (1) Elaboration of the scope of diversity of disulfide folding pathways, including the two opposite extreme models, represented by bovine pancreatic trypsin inhibitor (BPTI) and hirudin. (2) Demonstration of experimental evidence accounting for the underlying mechanism of the folding diversity. (3) Discussion of the convergence between the extreme models of oxidative folding and models of conventional conformational folding (framework model, hydrophobic collapse model). © 2011 American Chemical Society.


Louis E.D.,Columbia University | Ferreira J.J.,Institute of Molecular Medicine
Movement Disorders | Year: 2010

Essential tremor (ET) is among the more prevalent neurological disorders, yet prevalence estimates have varied enormously, making it difficult to establish prevalence with precision. We: (1) reviewed the worldwide prevalence of ET in population-based epidemiological studies, (2) derived as precisely as possible an estimate of disease prevalence, and (3) examined trends and important differences across studies. We identified 28 population-based prevalence studies (19 countries). In a meta-analysis, pooled prevalence (all ages) = 0.9%, with statistically significant heterogeneity across studies (I2 = 99%, P < 0.001). In additional descriptive analyses, crude prevalence (all ages) = 0.4%. Prevalence increased markedly with age, and especially with advanced age. In the meta-analysis, prevalence (age ≥ 65 years) = 4.6%, and in additional descriptive analyses, median crude prevalence (age ≥ 60-65) = 6.3%. In one study of those age ≥ 95 years, crude prevalence = 21.7%. Several studies reported ethnic differences in prevalence, although more studies are needed. Greater than one-third of studies show a gender difference, with most demonstrating a higher prevalence among men. This possible gender preference is interesting given clinical, epidemiological, and pathological associations between ET and Parkinson's disease. Precise prevalence estimates such as those we provide are important because they form the numerical basis for planned public health initiatives, provide data on the background occurrence of disease for family studies, and offer clues about the existence of environmental or underlying biological factors of possible mechanistic importance. © 2010 Movement Disorder Society.


Senge M.O.,Trinity College Dublin | Senge M.O.,Institute of Molecular Medicine
Chemical Communications | Year: 2011

Advances in the synthesis of unsymmetrically meso substituted porphyrins are based on the development of new total syntheses and porphyrin functionalization methods. These methods have replaced earlier mixed condensation reactions and give synthetic access to almost any desired meso-substituted porphyrin. They include the complete series of porphyrin homologues and regioisomers of the Ax-series with either alkyl or aryl residues, and numerous examples of ABCD-type chromophores. The syntheses are based on a combination of classic functionalization reactions, the use of organolithium reagents in SNAr reactions, and organometallic reactions with Pd, Ni, Cr, Ru, B, and Sn catalysis. This feature article gives an account of our work in the past decade to develop synthetic methods for the Ax- and ABCD-type porphyrins and their use as optical materials and photosensitizers. © 2011 The Royal Society of Chemistry.

Loading Institute of Molecular Medicine collaborators
Loading Institute of Molecular Medicine collaborators